Acceleron Pharma Inc. (XLRN) and Sesen Bio Inc. (NASDAQ:SESN) Contrasting side by side

Acceleron Pharma Inc. (NASDAQ:XLRN) and Sesen Bio Inc. (NASDAQ:SESN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 43 163.56 N/A -2.59 0.00
Sesen Bio Inc. 1 0.00 N/A -0.54 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Acceleron Pharma Inc. and Sesen Bio Inc.


Table 2 has Acceleron Pharma Inc. and Sesen Bio Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. 0.00% -35.9% -33.4%
Sesen Bio Inc. 0.00% -73.8% -31%

Volatility & Risk

A 1.32 beta means Acceleron Pharma Inc.’s volatility is 32.00% more than S&P 500’s volatility. Sesen Bio Inc.’s 115.00% more volatile than S&P 500 volatility due to the company’s 2.15 beta.


The current Quick Ratio of Acceleron Pharma Inc. is 19.3 while its Current Ratio is 19.3. Meanwhile, Sesen Bio Inc. has a Current Ratio of 8.5 while its Quick Ratio is 8.5. Acceleron Pharma Inc. is better positioned to pay off its short-term and long-term debts than Sesen Bio Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Acceleron Pharma Inc. and Sesen Bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 2 2 2.50
Sesen Bio Inc. 0 0 0 0.00

Acceleron Pharma Inc.’s upside potential currently stands at 45.13% and an $61 average price target. Competitively Sesen Bio Inc. has an average price target of $1, with potential downside of -19.03%. The information presented earlier suggests that Acceleron Pharma Inc. looks more robust than Sesen Bio Inc. as far as analyst belief.

Institutional & Insider Ownership

Acceleron Pharma Inc. and Sesen Bio Inc. has shares held by institutional investors as follows: 86.1% and 45.1%. Acceleron Pharma Inc.’s share held by insiders are 13.9%. Competitively, insiders own roughly 6.56% of Sesen Bio Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 2.61% -0.92% -0.66% -23.28% 18.82% -3.31%
Sesen Bio Inc. -3.08% 11.5% 54.58% -29.61% -55.16% -11.27%

For the past year Acceleron Pharma Inc. has stronger performance than Sesen Bio Inc.


On 7 of the 9 factors Acceleron Pharma Inc. beats Sesen Bio Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.